[ad_1]
GOTTINGEN, Germany, June 10 / PRNewswire / – – A broader portfolio for the development and production of biotech drugs
– Set the course for successful integration
Sartorius, a leading international partner in the biopharmaceutical research and industry, has successfully completed the acquisition of selected life sciences businesses from Danaher Corporation. The transaction was completed on April 30, 2020 after receiving the required antitrust approvals.
“The acquisition of this portfolio is another milestone for Sartorius. We have acquired strategically and operationally appropriate businesses for both divisions. We are pleased to welcome around 300 new Sartorius employees and, together, to be even more relevant to our biopharmaceuticals and Para become life science customers, “said Sartorius CEO Dr. Joachim Kreuzburg. Sartorius paid a purchase price of $ 825 million for the acquisition. The integration of the businesses acquired in the two divisions of the Sartorius Group has been prepared since the signing of the purchase agreement on October 19, 2019 and can now start immediately after the agreement has been concluded despite the special framework conditions during the pandemic crisis.
Sartorius’ acquired businesses, which generated sales of approximately $ 170 million in 2019, include various laboratory and bioprocess technologies that complement the positioning of both Sartorius divisions. The expanded offering supports customers even more comprehensively in the development of biotech drugs and vaccines, as well as in the safe and efficient production of such drugs. Sartorius is thus expanding its market positions in the field of bioanalytics and in important areas of biotech drug manufacturing.
The FortéBio business for the analysis of tagless biomolecules includes innovative devices for the analysis of proteins, biosensors and reagents that are used in drug discovery and integrated in the bioanalytical area within the Products and Services division of Sartorius Lab. Products are based on patented Biolayer interferometry technology and perform real-time analysis of various biomolecular interactions. The company employs around 200 people worldwide with production facilities in Fremont, California, USA. USA, and Shanghai, China, and contributes a little less than half to the turnover of the acquired portfolio.
With the chromatography systems and gels also purchased, Sartorius is expanding the portfolio of its bioprocess solutions division in the post-processing area. The business addresses a key step in reprocessing biopharmaceuticals and includes reusable and disposable technologies, columns and gels. Positioning in post-processing is reinforced by other select product groups in the areas of stainless steel hollow fiber and disposable cross-flow filter systems and flow kits. The SoloHill business unit is also assigned to the bioprocess solutions division, which includes microcarrier technology and particle validation standards for cell culture processes and other bioprocesses. The various units together employ around 100 people at their locations in Portsmouth, Britain, Cergy, France, Ann Arbor, Michigan, USA. USA, and Hopkinton, Massachusetts, USA. USA
Sartorius had already announced the implications of the transaction on the financial forecast for the current fiscal year when the first quarter results were published on April 21, 2020. The corresponding publication can be found here
https://www.sartorius.com/en/company-de/newsroom-de.
This publication contains statements on the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from these statements. Sartorius assumes no obligation to update such statements in light of new information or future events.
Sartorius in a nutshell
The Sartorius Group is a leading international partner in biopharmaceutical research and industry. The Laboratory Products and Services Division focuses on research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies and academic research institutions with innovative laboratory instruments and consumables. The Bioprocess Solutions Division contributes a broad portfolio of products with a focus on disposable solutions to the fact that biotech drugs and vaccines are manufactured safely and efficiently. The group grows in double digits a year on average and regularly complements its portfolio with acquisitions of complementary technologies. In fiscal year 2019, the company generated sales of around 1.83 billion euros. At the end of 2019, more than 9,000 employees were working at the Group’s 60 production and sales locations for clients around the world.
Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn.
Logo – https://mma.prnewswire.com/media/1123369/Sartorius_Logo.jpg
Contact
Petra Kirchhoff
Head of Corporate Communications and Investor Relations
+49 (0) 551-308-1686
[email protected] [1] https://www.sartorius.com
1. https://www.sartorius.com/
[ad_2]
